Literature DB >> 23494246

[Developmental process of DGPPN quality indicators].

I Großimlinghaus1, P Falkai, W Gaebel, B Janssen, D Reich-Erkelenz, T Wobrock, J Zielasek.   

Abstract

BACKGROUND: Valid and feasible quality indicators can measure healthcare quality and show potential for improvement in care. The German Association for Psychiatry and Psychotherapy (DGPPN) has developed trans-sectoral quality indicator sets for four mental disorders with high prevalence (alcohol dependence, dementia, depression and schizophrenia). MATERIAL AND
METHOD: The DGPPN followed a structured multistage process and used guideline recommendations and the results of systematic evidence searches as the basis for the development of these quality indicators. This was followed by a structured consensus process for all quality indicators.
RESULTS: Four evidence and consensus-based, diagnosis-specific and trans-sectoral quality indicator sets have been developed.
CONCLUSION: It is possible to develop quality indicators on the basis of guideline recommendations. The implementation of the DGPPN quality indicators will play a crucial role in order to evaluate their utility and feasibility as quality measures for German mental healthcare.

Entities:  

Mesh:

Year:  2013        PMID: 23494246     DOI: 10.1007/s00115-012-3705-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  64 in total

Review 1.  Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders.

Authors:  William R Miller; Paula L Wilbourne
Journal:  Addiction       Date:  2002-03       Impact factor: 6.526

2.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

3.  A meta-analysis of the effects of cognitive therapy in depressed patients.

Authors:  V Gloaguen; J Cottraux; M Cucherat; I M Blackburn
Journal:  J Affect Disord       Date:  1998-04       Impact factor: 4.839

4.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

Review 5.  Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

Authors:  Edward V Nunes; Frances R Levin
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

Review 6.  Psychoeducation for schizophrenia.

Authors:  E Pekkala; L Merinder
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 7.  Combined pharmacotherapy and psychological treatment for depression: a systematic review.

Authors:  Sandro Pampallona; Paola Bollini; Giuseppe Tibaldi; Bruce Kupelnick; Carmine Munizza
Journal:  Arch Gen Psychiatry       Date:  2004-07

8.  Cognitive--behavioural therapy and family intervention for relapse prevention and symptom reduction in psychosis: randomised controlled trial.

Authors:  Philippa A Garety; David G Fowler; Daniel Freeman; Paul Bebbington; Graham Dunn; Elizabeth Kuipers
Journal:  Br J Psychiatry       Date:  2008-06       Impact factor: 9.319

9.  OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis. One-year follow-up of a randomised controlled trial.

Authors:  M Nordentoft; P Jeppesen; M Abel; P Kassow; L Petersen; A Thorup; G Krarup; R Hemmingsen; P Jørgensen
Journal:  Br J Psychiatry Suppl       Date:  2002-09

10.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Authors:  Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

View more
  5 in total

1.  [Voluntary and mandatory quality assurance in mental health care: European examples].

Authors:  A Bramesfeld; G Willms; J Szecsenyi
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  [Assessment of quality indicators with routine data: Presentation of a feasibility test in ten specialist clinics for psychiatry and psychotherapy].

Authors:  I Großimlinghaus; P Falkai; W Gaebel; A Hasan; M Jänner; B Janssen; D Reich-Erkelenz; L Grüber; V Böttcher; T Wobrock; J Zielasek
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

3.  [DGPPN recommendations on quality indicators for schizophrenia].

Authors:  I Großimlinghaus; I Hauth; P Falkai; B Janssen; A Deister; A Meyer-Lindenberg; C Roth-Sackenheim; F Schneider; T Wobrock; R Zeidler; W Gaebel
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

Review 4.  Identifying primary care quality indicators for people with serious mental illness: a systematic review.

Authors:  Christoph Kronenberg; Tim Doran; Maria Goddard; Tony Kendrick; Simon Gilbody; Ceri R Dare; Lauren Aylott; Rowena Jacobs
Journal:  Br J Gen Pract       Date:  2017-07-03       Impact factor: 5.386

5.  The influence of cross-sectoral treatment models on patients with mental disorders in Germany: study protocol of a nationwide long-term evaluation study (EVA64).

Authors:  Anne Neumann; Enno Swart; Dennis Häckl; Roman Kliemt; Stefanie March; Denise Küster; Katrin Arnold; Thomas Petzold; Fabian Baum; Martin Seifert; Jessika Weiß; Andrea Pfennig; Jochen Schmitt
Journal:  BMC Psychiatry       Date:  2018-05-18       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.